News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer



10/30/2013 8:19:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FLEMINGTON, N.J., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced data from a preclinical study supporting further evaluation of its lead compound onapristone as a potential treatment for castration-resistant prostate cancer (CRPC). Results were presented during a poster session on Thursday, October 24 and in an oral presentation on Saturday, October 26 at the 20th Annual 2013 Prostate Cancer Foundation (PCF) Scientific Retreat, held October 24-26, 2013 in National Harbor, Md.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES